Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non-small cell lung cancer: A case report.

Thoracic cancer - 1 Apr 2023

Ikeo Satoshi, Yasuda Naoaki, Sakai Yuki, Hayashi Yasuyuki, Sokai Akihiko, Iwata Toshiyuki, Nishimura Takashi

Abstract excerpt

Mesenchymal epithelial transition factor receptor (MET) tyrosine kinase inhibitors (MET-TKIs) have been approved for the treatment of non-small cell lung cancers with MET exon 14 skipping mutations. Transient asymptomatic pulmonary opacities (TAPOs) associated with epidermal growth factor receptor (EGFR)-TKIs have been reported. Here, we report a case wherein ground-glass opacities (GGOs) appeared during the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Exons

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Protein Kinase Inhibitors

Share to Proto-Oncogene Proteins c-met

Source

Open in PubMed Open full text

Identifiers

PMID: 36810936
DOI: 10.1111/1759-7714.14831
PMCID: PMC10067352

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Transient asymptomatic pulmonary opacities in a patient with MET exon 14 skipping non-small cell lung cancer: A case report.PMID 36810936Read ↗

EGFR-mutant Non-small Cell Lung Cancer Accompanied by Transient Asymptomatic Pulmonary Opacities Successfully Treated with "Stop-And-Go" Osimertinib.Semantic proximity Read ↗

EGFR Mutation Rates Correlate with Age at Diagnosis and Tumor Characteristics in Patients with Pulmonary Ground-Glass OpacitiesSemantic proximity Read ↗

Early metastasis detected in patients with multifocal pulmonary ground-glass opacities (GGOs).Semantic proximity Read ↗

Osimertinib in Pulmonary Manifestations: Two Case Reports and Review of the Literature.Semantic proximity Read ↗

Age-Associated Targetable Genomic Alterations and PD-L1 Expression in 2509 Patients With Pulmonary Ground-Glass Opacities.Semantic proximity Read ↗

Characteristic computed tomography features in mesenchymal-epithelial transition exon14 skipping-positive non-small cell lung cancer.Semantic proximity Read ↗

Ground glass opacities: Imaging, pathology, and gene mutations.Semantic proximity Read ↗

The Impact of EGFR Tyrosine Kinase Inhibitor on the Natural Course of Concurrent Subsolid Nodules in Patients with Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Safety of Tepotinib Challenge after Capmatinib-Induced Pneumonitis in a Patient with Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation: A Case Report.Semantic proximity Read ↗

TAPO in first-line osimertinib therapy and continuation of osimertinib.Semantic proximity Read ↗

Postoperative EGFR-TKI treatment on residual multiple ground-glass nodules after resection for lung adenocarcinoma:a case report and literature reviewSemantic proximity Read ↗

Case report: MSI-H, EGFR mutation, and ground-glass nodules as diffuse pulmonary hematogenous metastases.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.